dipeptidyl
peptidas
transmembran
glycoprotein
molecular
mass
kda
origin
known
cell
surfac
marker
cluster
differenti
kameoka
tanaka
nojima
schlossman
morimoto
ohnuma
dang
morimoto
human
consist
short
amino
acid
intracellular
domain
transmembran
region
extracellular
domain
possess
dipeptidyl
peptidas
activ
select
cleav
ntermin
dipeptid
peptid
prolin
alanin
lesser
extent
serin
penultim
posit
wide
express
differ
organ
includ
kidney
gastrointestin
tract
liver
bone
marrow
well
surfac
variou
cell
type
stromal
stem
epitheli
endotheli
immun
cell
thul
et
al
wauman
baert
keho
lambeir
de
meester
moreov
also
exist
solubl
form
bodi
fluid
varin
et
al
compos
extracellular
amino
acid
show
signific
activ
casroug
et
al
durinx
et
al
known
gutderiv
incretin
glucagon
like
glucos
depend
insulinotrop
peptid
gip
essenti
preserv
glucos
homeostasi
ahren
hugh
baggio
drucker
rapidli
degrad
circul
gip
decad
inhibitor
commonli
call
gliptin
work
valuabl
oral
antidiabet
drug
oad
treatment
type
diabet
mellitu
extend
halflif
nativ
incretin
marguet
et
al
mari
et
al
first
sitagliptin
approv
food
drug
administr
fda
adult
numer
gliptin
gener
includ
saxagliptin
alogliptin
vildagliptin
linagliptin
teneligliptin
trelagliptin
omarigliptin
investig
past
decad
demonstr
may
broad
biolog
function
beyond
glucos
metabol
evidenc
variou
substrat
widespread
express
specif
cleav
larg
number
cytokin
chemokin
peptid
hormon
involv
regul
immun
system
broxmey
et
al
proost
et
al
also
capabl
modul
lymphocyt
function
mani
aspect
especi
cell
activ
signal
transduct
accordingli
assum
immun
regulatori
function
potenti
therapeut
use
treatment
autoimmun
inflammatori
diseas
howev
limit
studi
clinic
evid
demonstr
immun
modulatori
function
precis
mechan
underli
process
review
focus
function
inhibitor
may
provid
new
clue
clinic
applic
gliptin
effect
immun
system
may
exert
effect
immun
system
two
mechan
one
hand
enzymat
function
result
decomposit
target
substrat
inact
activ
fragment
exert
direct
effect
immun
respons
hand
act
potent
costimulatori
molecul
process
cell
signal
transduct
ohnuma
et
al
exert
noncatalyt
function
via
bind
fibronectin
adenosin
deaminas
ada
cxc
chemokin
receptor
cheng
abdelghani
pauli
herrera
et
al
ohnuma
et
al
ohnuma
et
al
bestknown
signal
transduct
interact
ada
ada
enzym
catalyz
hydrolyt
deamin
adenosin
inosin
martin
huguet
centel
franco
long
known
high
concentr
adenosin
inhibit
prolifer
lymphocyt
green
chan
ada
bound
function
could
counteract
inhihitori
effect
extracellular
adenosin
accordingli
pathway
consid
essenti
model
tcell
activ
beyond
cell
capabl
transendotheli
migrat
vitro
appear
highli
express
indic
potenti
function
cell
migrat
brezinschek
lipski
galea
vita
oppenheimermark
besid
lymphocyt
identifi
express
b
cell
natur
killer
nk
cell
dendrit
cell
dc
macrophag
well
tabl
howev
immun
regulatori
function
cell
remain
poorli
character
previous
demonstr
higher
express
cell
surfac
cell
correl
helper
type
like
phenotyp
wherea
lower
express
associ
phenotyp
willheim
et
al
furthermor
high
surfac
express
also
correl
product
cytokin
reinhold
et
al
willheim
et
al
dc
potent
antigenpres
cell
apc
special
initi
immun
respons
direct
activ
differenti
lymphocyt
pacheco
et
al
report
deaminas
activityindepend
way
ada
interact
cell
surfac
complex
subsequ
anchor
dc
surfac
adaanchor
protein
trigger
costimul
lead
augment
tcell
activ
pattern
mark
increas
product
proimmflamatori
cytokin
includ
interferon
gamma
tumor
necrosi
factor
tnf
interleukin
il
pacheco
et
al
contrast
knockout
mice
lead
reduct
immun
respons
preller
et
al
upregul
cytokin
yan
gessner
dietel
schmiedek
fan
find
confirm
import
prolifer
function
cell
cell
cell
prolifer
regul
transform
growth
factor
tgf
play
import
role
pathogenesi
autoimmun
inflamm
regulatori
treg
lymphocyt
exert
immunosuppress
effect
mean
direct
celltocel
interact
secret
cytokin
shao
yu
shen
found
express
enzymat
activ
higher
human
cell
treg
cell
bengsch
et
al
phenotyp
analysi
reveal
cell
contain
cell
bengsch
et
al
knockout
result
signific
reduct
cytokin
mice
lung
transplant
yamada
et
al
author
assum
modul
cell
via
costimulatori
effect
signal
lymphocyt
activ
yamada
et
al
howev
investig
downstream
signal
perform
import
cell
prolifer
cell
show
increas
wang
et
al
winer
et
al
describ
correl
augment
activ
along
mark
increas
cytokin
includ
pinheiro
et
al
found
sitagliptin
treatment
could
complet
abolish
express
peripher
blood
mononuclear
cell
pbmc
stimul
phytohemagglutinin
pha
healthi
volunt
inhibit
differenti
vitro
pinheiro
et
al
thu
assum
may
also
involv
prolifer
contrari
express
lower
membran
treg
cell
mandapathil
et
al
character
neg
select
marker
human
treg
garcia
santana
tung
gulnik
base
marker
analysi
human
natur
regulatori
cell
ntreg
identifi
five
differ
cell
subset
repres
distinct
stage
matur
respect
schiavon
et
al
addit
significantli
increas
treg
expans
nonobes
diabet
nod
mice
tian
et
al
indic
inhibit
may
respons
prolifer
treg
lymphocyt
martineznavio
identifi
ada
promot
augment
gener
high
treg
mechan
seem
mainli
depend
enzymat
activ
martineznavio
et
al
accordingli
consid
exert
import
regulatori
role
gener
treg
previous
demonstr
high
cell
repres
activ
cell
phenotyp
may
offer
characterist
marker
success
memori
develop
hatano
ohnuma
yamamoto
dang
morimoto
ibegbu
et
al
one
molecul
express
cell
provid
costimulatori
signal
cell
activ
gambl
et
al
interestingli
costimul
cell
result
greater
cytotox
effect
induc
costimul
pathway
hatano
et
al
modul
lymphocyt
may
use
costimulatori
transduct
mediat
earli
growth
respons
hatano
et
al
pinheiro
et
al
addit
effect
cell
also
contribut
modul
matur
prolifer
immunoglobulin
isotyp
switch
b
cell
buhl
et
al
morimoto
et
al
less
freshli
isol
b
cell
express
antigen
peripher
blood
healthi
donor
common
variabl
immunodefici
cvid
patient
upon
activ
pokewe
mitogen
fraction
human
b
cell
increas
around
buhl
et
al
suggest
involv
bcell
activ
specif
suppress
activ
reduc
b
cell
activ
dosedepend
manner
buhl
et
al
inhibitor
could
suppress
enzymat
activ
therebi
trigger
certain
signal
transduct
pathway
lead
decreas
dna
synthesi
b
cell
buhl
et
al
howbeit
author
fail
identifi
detail
molecular
mechan
one
import
function
b
lymphocyt
secret
immunoglobulin
ig
signific
chang
ig
secret
b
cell
mice
identifi
may
trigger
chang
differ
cytokin
includ
yan
marguet
dober
reutter
fan
differ
ig
secret
observ
anoth
studi
vora
et
al
publish
morimoto
found
express
memoryhelp
popul
respond
recal
antigen
induc
bcell
igg
synthesi
morimoto
et
al
buhl
et
al
measur
igm
concentr
highli
purifi
b
cell
differ
inhibitor
concentr
found
dosedepend
decreas
igm
secret
buhl
et
al
base
find
mediat
bcell
ig
secret
may
either
celldepend
bcell
respons
direct
effect
b
cell
buhl
et
al
show
freshli
isol
human
nk
cell
express
low
amount
buhl
et
al
furthermor
author
identifi
specif
inhibitor
suppress
dna
synthesi
cell
cycl
progress
thu
conclud
involv
modul
nk
cell
prolifer
may
also
involv
natur
cytotox
nk
cell
verifi
observ
nk
cell
cytotox
tumour
cell
diminish
rat
substrain
model
lung
metastasi
shingu
et
al
one
underli
mechan
tumor
target
cell
directli
adher
nk
cell
via
addit
nk
cell
exert
cytotox
via
secretori
lysosom
interestingli
found
membran
secretori
lysosom
nk
cell
mean
proteom
analysi
casey
mead
hewitt
whether
secretori
lysosom
could
also
mediat
nk
cell
cytotox
remain
identifi
first
descript
express
dc
report
gliddon
colleagu
bovin
affer
lymph
lymph
node
gliddon
howard
obes
human
rodent
demonstr
increas
express
dc
viscer
adipos
tissu
zhong
et
al
consid
express
dc
confer
abil
modifi
macrophagederiv
chemokin
mdc
may
stimul
polar
cell
attract
induc
respons
polar
cell
gliddon
howard
furthermor
complex
dc
capabl
stimul
cell
prolifer
via
adenosin
degrad
mix
lymphocyt
reaction
mlr
assay
use
tcelldc
cocultur
zhong
et
al
find
disclos
novel
mechan
paracrin
regul
inflamm
express
macrophag
viscer
also
identifi
high
fat
diet
hfd
induc
genet
obes
obob
mice
zhong
et
al
longterm
inhibit
alogliptin
decreas
viscer
macrophag
content
hi
apo
mous
model
shah
et
al
similarli
ikedo
et
al
identifi
alogliptin
inhibit
accumul
macrophag
intracrani
aneurysm
sd
rat
verifi
effect
independ
ikedo
et
al
silenc
express
shrna
target
hepatocyt
hfd
induc
obes
mice
also
suppress
macrophag
inflamm
viscer
ghorpad
et
al
furthermor
zhong
colleagu
report
macrophageexpress
bind
ada
result
tcell
prolifer
via
modul
adenosin
concentr
develop
adipos
inflamm
zhong
et
al
find
disclos
signific
role
macrophag
prolifer
function
tabl
express
function
immun
cell
function
refer
cell
high
express
correl
product
cytokin
preller
et
al
reinhold
et
al
willheim
et
al
cell
low
express
inhibit
lead
upregul
cytokin
willheim
et
al
yan
et
al
cell
highest
express
cell
correl
product
cytokin
bengsch
et
al
yamada
et
al
treg
cell
negativelow
express
inhibit
lead
upregul
treg
garcia
santana
et
al
mandapathil
et
al
schiavon
et
al
tian
et
al
cell
highneg
express
mediat
costimul
cell
hatano
et
al
ibegbu
et
al
b
cell
low
express
correl
b
cell
activ
buhl
et
al
klemann
et
al
morimoto
et
al
yan
et
al
low
express
correl
prolifer
cytotox
nk
cell
buhl
et
al
shingu
et
al
yan
et
al
dc
posit
express
togeth
ada
stimul
tcell
prolifer
gliddon
howard
zhong
et
al
macrophag
posit
express
regul
macrophag
polar
shah
et
al
zhuge
et
al
note
ada
adenosin
deaminas
dc
dendrit
cell
dipeptidyl
peptidas
nk
cell
natur
killer
cell
cell
helper
type
cell
cell
helper
type
cell
cell
cell
treg
cell
regulatori
cell
addit
found
predominantli
express
macrophag
white
hfd
induc
obes
mice
zhuge
et
al
indic
effect
regul
macrophag
polar
macrophag
inflammatori
also
known
cc
motif
chemokin
ligand
ccl
chemokin
substrat
report
cleavag
convert
effici
chemoattract
proost
et
al
linagliptin
fail
induc
macrophag
polar
exert
insulinsensit
effect
mice
zhuge
et
al
suggest
regul
polar
may
mediat
although
respons
proteolyt
cleavag
wide
rang
substrat
research
focus
incretin
hormon
gip
treatment
ahren
hugh
baggio
drucker
unniappan
et
al
addit
incretin
cytokin
broxmey
et
al
oleari
et
al
wesley
mcgroarti
homoyouni
chemokin
barreira
da
silva
et
al
de
la
luz
sierra
et
al
holland
et
al
janssen
et
al
oravecz
et
al
proost
et
al
proost
et
al
qin
et
al
neuropeptid
frerker
et
al
guieu
et
al
identifi
substrat
tabl
therebi
allow
regul
immun
respons
plenti
chemokin
cytokin
recogn
target
among
chemokin
cxc
motif
ligand
also
known
stromal
cellderiv
popular
one
chemokin
attract
variou
progenitor
cell
stem
cell
leukocyt
neuron
angioblastendotheli
cell
tumor
cell
thu
involv
plenti
process
angiogenesi
hematopoiesi
tissu
repair
eg
myocardi
infarct
mi
ischeam
stroke
bromag
davidson
yellon
kubota
et
al
yang
et
al
zhang
et
al
act
g
proteincoupl
proteolyt
cleavag
gener
result
reduc
affin
loss
calciumdepend
signal
chemotact
properti
de
la
luz
sierra
et
al
janssen
et
al
addit
play
gener
role
regul
activ
cytokin
identifi
truncat
cytokin
fibroblast
growth
factor
granulocytemacrophag
gm
colonystimul
factor
csf
granulocyt
g
csf
erythropoietin
epo
thu
resultantli
decreas
activ
function
broxmey
et
al
oleari
et
al
wesley
et
al
besid
plenti
cytokin
potenti
truncat
site
includ
ou
oleari
broxmey
howev
whether
cytokin
true
truncat
site
need
specif
determin
via
mass
spectrometri
compar
analysi
biolog
assay
vitro
vivo
necessari
determin
function
activ
truncat
molecul
differ
fulllength
form
protein
furthermor
cytokin
regul
may
via
complic
interact
factorsimmun
cell
rather
direct
truncat
exampl
interact
act
costimulatori
signal
cell
receptor
signal
result
enhanc
secret
de
meester
et
al
kameoka
et
al
likewis
steinbrech
et
al
suggest
suppress
may
stimul
secret
activ
cell
henc
antiinflammatori
effect
mice
model
experiment
autoimmun
encephalomyel
eae
steinbrech
et
al
taken
togeth
cytokin
chemokin
peptid
hormon
mention
tabl
meant
cover
identifi
factor
rather
describ
wide
varieti
biolog
molecul
may
truncat
regul
link
diseas
summar
tabl
includ
limit
autoimmun
diabet
inflammatori
bowel
diseas
ibd
rheumatoid
arthriti
ra
allograft
reject
tumor
cardiovascular
diseas
cvd
asthma
infecti
diseas
bullou
pemphigoid
bp
howev
effect
diseas
controversi
inhibit
autoimmun
diabet
type
diabet
mellitu
autoimmun
disord
character
destruct
pancreat
cell
inadequ
insulin
secret
roep
tree
circumst
even
slight
preserv
residu
cell
mass
may
result
signific
benefit
clinic
palmer
et
al
unfortun
immunomodulatori
drug
report
induceassist
diseas
gliddon
howard
proost
et
al
unniappan
et
al
neuropeptid
npi
frerker
et
al
substanc
p
guieu
et
al
ccl
cc
motif
chemokin
ligand
cxcl
chemokin
cxc
motif
ligand
fibroblast
growth
factor
gcsf
granulocytecsf
gip
gastric
inhibitori
peptid
glp
hormon
glucagon
like
peptid
gmcsf
granulocytemacrophagecolonystimul
factor
grp
gastrinreleas
peptid
il
interleukin
interferon
gamma
ifngammainduc
itac
ifninduc
tcell
alphachemoattract
monocyt
chemotact
protein
mdc
macrophagederiv
chemokin
mig
monokin
induc
ifngamma
macrophag
inflammatori
npi
neuropeptidey
stromal
cellderiv
rant
regul
activ
normal
tcell
express
secret
transform
growth
tumor
necrosi
potenti
truncat
regul
rather
truncat
remiss
current
wide
appli
valuabl
monoor
combin
therapeut
oad
howev
portion
clinic
studi
indic
potenti
efficaci
regard
glycem
control
cell
preserv
autoimmun
diabet
character
increas
immun
respons
decreas
respons
addit
imbal
also
involv
pathogen
process
shao
et
al
describ
tabl
inhibit
downregul
phenotyp
upregul
cytokin
stimul
prolifer
treg
decreas
product
thu
suppos
potenti
treat
autoimmun
diabet
preclin
trial
inhibit
activ
shown
enhanc
islet
neogenesi
cell
surviv
reversedelay
onset
diabet
either
streptozotocin
stz
induc
anim
model
conarello
et
al
pospisilik
et
al
takeda
et
al
nod
mous
model
autoimmun
diabet
jels
vrang
van
witteloostuijn
mark
klein
tian
et
al
combin
therapi
proton
pump
inhibitor
ppi
increas
circul
level
gastrin
acut
diabet
nod
mice
result
restor
pancreat
insulin
content
insulin
secret
normoglycaemia
suarezpinzon
cembrowski
rabinovitch
treatment
stzinduc
mice
islet
transplant
prolong
surviv
islet
graft
kim
et
al
differ
kim
et
al
report
cell
mass
enhanc
nod
mice
combin
tolllik
receptor
agonist
agonist
alon
kim
et
al
previou
anim
studi
consid
cell
preserv
attribut
increas
conarello
et
al
kim
et
al
pospisilik
et
al
suarezpinzon
et
al
takeda
et
al
dysfunct
treg
thought
hallmark
geach
preclin
data
tian
colleagu
demonstr
upregul
treg
inhibit
associ
remiss
nod
mice
tian
et
al
possibl
suppress
result
chang
chemokin
diabet
nod
mice
thu
promot
migrat
treg
pancrea
fig
due
signific
result
anim
experi
numer
clinic
studi
conduct
investig
therapeut
effect
patient
four
placebocontrol
studi
investig
efficaci
sitagliptinvildagliptin
treatment
elli
et
al
farngren
persson
schweizer
foley
ahren
garg
et
al
hari
kumar
shaikh
prusti
two
studi
show
signific
reduct
treatment
week
respect
elli
et
al
farngren
et
al
two
studi
nt
show
treatmentrel
differ
garg
et
al
hari
kumar
et
al
metaanalysi
wang
et
al
reveal
addit
use
result
greater
decreas
level
compar
insulin
monotherapi
although
signific
wang
long
et
al
addit
trial
investig
effect
gliptin
cell
preserv
individu
newli
diagnos
sitagliptin
treatment
one
year
fail
result
signific
differ
cpeptid
secret
group
hari
kumar
et
al
likewis
griffin
colleagu
randomli
assign
particip
receiv
combin
therapi
oral
sitagliptin
ppi
lansoprazol
match
placebo
month
howev
differ
cpeptid
group
signific
griffin
thompson
gottschalk
kyllo
rabinovitch
two
trial
estim
gliptin
incap
preserv
cell
mass
autoimmun
diabet
latent
autoimmun
diabet
adult
lada
special
subtyp
interestingli
oneyear
prospect
studi
conduct
lada
patient
demonstr
combin
treatment
sitagliptin
patient
receiv
insulin
provid
signific
improv
paramet
islet
function
zhao
et
al
similarli
anoth
linagliptin
contribut
progress
increas
cpeptid
level
patient
lada
studi
johansen
et
al
tabl
effect
inhibit
autoimmuneinflammatori
diseas
autoimmun
diabet
reduct
patient
elli
et
al
farngren
et
al
treatment
efficaci
patient
garg
et
al
hari
kumar
et
al
zhao
et
al
cell
preserv
lada
patient
johansen
et
al
zhao
et
al
effect
cell
preserv
patient
griffin
et
al
hari
kumar
et
al
cell
preserv
anim
model
conarello
et
al
jels
et
al
kim
et
al
kim
et
al
pospisilik
et
al
suarezpinzon
et
al
takeda
et
al
tian
et
al
ibd
increas
risk
patient
wang
et
al
improv
coliti
anim
model
ban
et
al
salaga
et
al
salaga
et
al
ra
decreas
risk
patient
kim
et
al
seong
et
al
associ
patient
increas
diseas
sever
anim
model
busso
et
al
ospelt
et
al
allograft
reject
reject
suppress
anim
model
islet
lung
skin
transplant
jung
et
al
kim
et
al
zhai
et
al
zhao
et
al
cancer
associ
patient
barnett
et
al
green
et
al
leiter
et
al
mita
et
al
tumor
suppress
vitroin
anim
model
hcc
breast
cancer
melanoma
cml
multipl
myeloma
barreira
da
silva
et
al
herrmann
et
al
holland
et
al
nishida
et
al
qin
et
al
tumor
develop
vitroin
anim
model
pca
lung
cancer
crc
russo
et
al
shingu
et
al
wesley
et
al
xie
et
al
cvd
cardiovascular
safeti
patient
aroor
et
al
green
et
al
scirica
et
al
white
et
al
increas
risk
hf
patient
scirica
et
al
white
et
al
cardioprotect
anim
model
bostick
et
al
hocher
et
al
kubota
et
al
mulvihil
et
al
shah
et
al
connelli
et
al
zhang
et
al
effect
impair
cardiac
function
anim
model
mulvihil
et
al
yin
et
al
asthma
increas
airway
inflamm
anim
model
yan
et
al
decreas
airway
inflamm
anim
model
schmiedl
et
al
infecti
diseas
increas
risk
nasopharyng
urinari
tract
infect
associ
upper
respiratori
tract
infect
patient
amori
et
al
gambl
et
al
potenti
advers
effect
mer
patient
inn
et
al
raj
et
al
potenti
therapeut
effect
hcv
patient
decalf
et
al
riva
et
al
taken
togeth
exist
studi
fail
strongli
support
clinic
applic
either
glucos
control
cell
preserv
patient
contrari
conclus
obtain
clinic
trial
may
attribut
differ
baselin
characterist
includ
patient
cpeptid
level
diseas
durat
distinct
followup
length
differ
sampl
size
variabl
anoth
point
worth
note
suppress
alon
may
abl
complet
prevent
autoimmun
attack
cell
overt
condit
thu
addit
immunolog
measur
probabl
necessari
tidm
treatment
order
attenu
establish
autoimmun
besid
tradit
anim
model
unlik
provid
accur
predict
clinic
success
human
studi
substanti
genet
variat
environ
present
laboratori
rodent
futur
research
shift
toward
studi
human
be
consist
baselin
characterist
particip
addit
larger
sampl
size
longer
followup
durat
monitor
immun
paramet
cell
b
cell
cytokin
taken
consider
ibd
includ
crohn
diseas
cd
ulcer
coliti
uc
autoimmun
digest
system
diseas
character
chronic
remitt
progress
inflamm
gastrointestin
tract
abbott
yazbeck
geier
demuth
howarth
recent
research
disclos
potenti
associ
inhibit
risk
ibd
duan
zatorski
review
studi
role
glp
ibd
duan
rao
braunstein
toomey
zhong
zatorski
salaga
fichna
consid
lymphocyt
treg
macrophag
dc
proinflammatori
cytokin
may
involv
mediat
gut
immun
preclin
studi
anim
model
underli
mechan
limit
studi
includ
ban
et
al
salaga
et
al
salaga
et
al
administr
inhibitor
salaga
et
al
salaga
et
al
ban
et
al
could
markedli
attenu
coliti
mous
model
experiment
coliti
may
mediat
fig
downstream
signal
remain
unclear
need
explor
realworld
evid
present
opposit
conclus
anim
studi
studi
patient
treat
gliptin
reveal
preval
cd
significantli
higher
patient
treatment
control
retrospect
cohort
studi
use
unit
kingdom
clinic
practic
research
datalink
cprd
found
new
use
median
durat
year
associ
increas
risk
ibd
hazard
ratio
compar
antidiabet
medic
addit
hazard
ratio
gradual
increas
along
longer
durat
usag
reach
peak
three
four
year
wang
demonstr
weaktomoder
signal
ibd
associ
use
us
food
drug
administr
advers
event
report
system
faer
databas
li
et
al
perform
metaanalysi
random
control
trial
rct
associ
ibd
found
howbeit
subanalysi
identifi
oad
may
reduc
cd
risk
increas
uc
risk
note
analysi
may
underpow
detect
associ
due
limit
number
includ
trialsev
statist
imprecis
thu
suggest
associ
ibd
note
physician
cautiou
treat
diabet
patient
ibd
ra
chronic
system
inflammatori
diseas
unknown
etiolog
character
progress
destruct
articular
cartilag
eros
underli
bone
speiser
ho
verdeil
alter
activ
first
note
mice
ra
gotoh
hagihara
nagatsu
iwata
miura
gain
insight
pathophysiolog
role
arthriti
busso
et
al
explor
express
experiment
mice
model
arthriti
murin
antigeninduc
arthriti
aia
found
reduc
plasma
activ
mice
model
busso
et
al
secret
substrat
ra
synovi
fibroblast
rasf
crucial
involv
inflammatori
process
recruit
cell
monocyt
peripheri
rheumatoid
synovium
seki
selbi
haupl
winchest
mice
aia
diseas
sever
increas
due
lower
activ
synovi
fluid
result
increas
level
mice
fig
busso
et
al
major
extracellular
proteolyt
enzym
involv
cartilag
resorpt
matrix
metalloproteinas
mmp
serin
proteas
proost
et
al
ospelt
et
al
found
inhibit
serin
proteas
activ
promot
invas
rasf
cartilag
mous
model
ra
lead
increas
level
concert
downstream
effector
vitro
ospelt
et
al
result
indic
central
role
signal
protect
articular
cartilag
rasf
invas
busso
et
al
explor
express
ra
patient
also
found
reduc
plasma
activ
busso
et
al
concentr
greatli
elev
synovi
fluid
patient
ra
contrast
concentr
healthi
individu
kanb
takagishi
chen
howev
function
role
human
observ
present
cohort
find
contradict
anim
studi
larg
cohort
diabet
patient
initi
combin
therapi
appear
decreas
risk
autoimmun
diseas
includ
ra
hazard
ratio
compar
initi
combin
therapi
kim
et
al
similar
result
found
larg
populationbas
cohort
studi
conduct
seong
seong
yee
gwak
howev
use
unit
kingdom
cprd
douro
conduct
cohort
studi
among
patient
initi
oad
found
use
associ
increaseddecreas
risk
incid
ra
nevertheless
result
may
suggest
possibl
pharmacolog
pathway
prevent
treatment
ra
gliptin
contradictori
find
rodent
human
limit
usag
murin
model
elucid
function
human
ra
research
investig
mechan
distinct
assum
except
cytokinesimmun
cell
regul
particip
inflammatori
process
human
ra
futur
investig
specif
focus
direct
biolog
effect
human
ra
undoubtedli
contribut
better
understand
role
possibl
therapeut
target
ra
last
effect
therapeut
strategi
mani
endstag
diseas
organ
transplant
howev
one
biggest
challeng
maintain
longterm
surviv
graft
prevent
allograft
reject
studi
kim
et
al
demonstr
treatment
nod
mice
reduc
effect
autoimmun
islet
graft
surviv
partial
decreas
home
cell
pancreat
cell
pathway
fig
kim
et
al
moreov
sever
studi
investig
whether
inhibit
activ
play
role
acut
pulmonari
reject
treatment
proprodiphenyl
phosphon
deriv
abrog
acut
reject
preserv
earli
graft
function
pulmonari
transplant
anim
model
jung
et
al
zhai
et
al
recent
studi
yamada
group
conclud
blockad
promot
lung
allograft
accept
due
reduc
cell
infiltr
lower
express
increas
express
like
deriv
altern
activ
macrophag
yamada
et
al
result
expand
role
alloantigenmedi
immun
respons
moreov
knockout
mice
use
investig
potenti
role
allogen
skin
graft
reject
shown
knockout
mice
display
reduc
necrosi
graft
delay
graft
reject
significantli
reduc
secret
level
cytokin
increas
level
skin
transplant
zhao
et
al
addit
lower
percentag
cell
higher
percentag
treg
cell
detect
peripher
blood
lymphocyt
knockout
mice
studi
zhao
et
al
indic
defici
lead
feebler
reject
due
lower
activ
less
prolifer
host
immun
cell
far
still
clinic
studi
focus
potenti
effect
allograft
reject
futur
investig
field
necessari
may
expand
clinic
applic
increas
evid
demonstr
applic
immunotherapi
improv
clinic
outcom
cancer
encourag
find
experiment
work
regard
suppress
melanoma
liver
breast
tumor
barreira
da
silva
et
al
herrmann
et
al
holland
et
al
futur
clinic
studi
tabl
locat
inhibit
possibl
lead
tumor
develop
russo
et
al
shingu
et
al
wesley
et
al
xie
et
al
found
gene
ablat
pharmacolog
inhibit
notabl
prevent
hfdassoci
hepatocellular
carcinoma
hcc
progress
rat
model
carcinogentrigg
liver
cancer
downregul
chemokin
product
angiogenesi
fig
qin
et
al
holland
colleagu
investig
mechan
inhibit
reduc
tumor
growth
hcc
breast
cancer
syngen
mous
model
found
administr
sitagliptin
result
higher
concentr
eosinophil
chemoattract
known
target
truncat
tabl
increas
migrat
eosinophil
solid
tumor
holland
et
al
moreov
barreira
da
silva
et
al
show
melanoma
growth
significantli
delay
knockout
mice
tumortranspl
model
author
estim
cell
traffick
may
involv
barreira
da
silva
et
al
contrari
use
vitro
model
system
metastat
prostat
cancer
cell
wesley
indic
may
inhibit
malign
phenotyp
prostat
cancer
pca
enhanc
degrad
wesley
et
al
rat
model
lung
metastasi
drastic
chang
outcom
metastat
diseas
may
partial
mediat
nk
cell
cytotox
shingu
et
al
inhibit
diminish
effect
besid
experiment
studi
plenti
clinic
trial
also
conduct
assess
possibl
cancer
risk
includ
sitagliptin
green
et
al
alogliptin
mita
et
al
saxagliptin
leiter
et
al
linagliptin
barnett
et
al
trial
demonstr
gliptin
increas
tumor
risk
patient
zhao
perform
metaanalysi
total
trial
enrol
signific
associ
detect
use
gliptin
cancer
develop
zhao
et
al
indic
safeti
rather
benefit
gliptin
tumor
differ
conclus
anim
model
clinic
trial
may
attribut
rel
weak
effect
tumor
immun
complex
tumor
microenviron
human
be
studi
fulli
character
effect
variou
clinic
set
requir
comprehens
evalu
administr
cancer
patient
patient
increas
risk
develop
cvd
prevail
caus
death
worldwid
atherosclerosi
main
underli
factor
cvd
consid
chronic
inflammatori
diseas
variou
cell
type
involv
pathogen
process
includ
differenti
activ
b
lymphocyt
monocyt
macrophag
dc
neutrophil
endotheli
cell
rafieiankopaei
setorki
doudi
baradaran
nasri
abund
preclin
evid
implic
benefici
role
inhibit
atherosclerosi
cvd
summar
sever
review
aroor
manriqueacevedo
demarco
avogaro
fadini
vedantham
kluever
deindl
zhong
maiseyeu
davi
rajagopalan
macrophag
play
central
role
develop
atherosclerosi
mainten
local
inflammatori
respons
propag
plaqu
develop
promot
thrombosi
barrett
shah
et
al
identifi
decreas
aortic
plaqu
exert
antiatherosclerot
effect
reduc
inflamm
via
inhibit
macrophag
activationrecruit
ldl
receptordefici
mous
model
indic
import
implic
use
class
drug
atherosclerosi
shah
et
al
sitagliptin
found
attenu
advers
remodel
follow
mi
fischer
rat
stzdiabet
connelli
et
al
notabl
inhibit
normoglycem
rodent
also
significantli
improv
cardiac
function
decreas
infarct
size
within
day
mi
hocher
sharkovska
mark
klein
pfab
kubota
et
al
endotheli
progenitor
cell
epc
deriv
bone
marrow
known
promot
vascular
repair
neoangiogenesi
importantli
reveal
inhibit
potenti
enhanc
deliveri
epc
toward
injur
vascular
site
mi
rat
hocher
et
al
probabl
due
increas
concentr
fig
clinic
trial
patient
treat
linagliptin
identifi
signific
increas
epc
fadini
et
al
addit
epc
describ
could
also
attract
stem
cell
zhang
et
al
report
combin
overexpress
mesenchym
stem
cell
msc
diprotin
inhibit
rat
mi
model
enhanc
msc
recruit
penetr
ischem
myocardium
via
pathway
lead
inhibit
myocardi
ischemiainduc
apoptosi
tissu
angiogenesi
improv
heart
function
mi
furthermor
cardioprotect
effect
abolish
pretreat
antagonist
signal
transduc
activ
transcript
inhibitor
mice
mi
indic
inhibit
may
direct
protect
effect
postmi
heart
signal
pathway
kubota
et
al
fadini
also
report
profil
increas
progenitor
cell
kdr
epc
bright
monocyt
along
significantli
elev
patient
treatment
linagliptin
fadini
et
al
demonstr
potenti
favor
cardiovascular
implic
gliptin
contrast
chronic
administr
vildagliptin
normoglycem
rat
either
prior
week
induct
mi
fail
avert
reduct
eject
fraction
modifi
cardiac
remodel
yin
sillj
meissner
van
gilst
de
boer
inconsist
find
may
attribut
long
durat
diseas
accordingli
assum
inhibit
substanti
protect
effect
cardiac
function
well
establish
longterm
postmi
cardiac
remodel
model
reduc
interstiti
fibrosi
heart
observ
select
treat
j
mice
fed
high
fathigh
fructos
diet
week
bostick
et
al
consist
find
mulvihil
et
al
identifi
young
normoglycem
mice
also
exhibit
signific
reduct
cardiac
fibrosi
cardioprotect
respons
transvers
aortic
constrict
tac
surgeri
mulvihil
et
al
surprisingli
diabet
mice
treat
exhibit
modest
cardiac
hypertrophi
impair
cardiac
function
dysregul
express
gene
protein
involv
inflamm
cardiac
fibrosi
mulvihil
et
al
assum
metabol
statu
may
affect
cardiovascular
benefit
inhibit
remain
investig
although
clinic
studi
emphas
cardiovascular
safeti
evid
reduc
major
advers
cardiovascular
event
differ
observ
aroor
et
al
green
et
al
scirica
et
al
white
et
al
cardiovascular
outcom
trial
reveal
increas
hospit
rate
heart
failur
hf
among
subject
treat
saxagliptin
alogliptin
scirica
et
al
white
et
al
accord
result
specul
cardiovascular
benefit
inhibit
may
depend
diseas
durat
transient
longterm
metabol
phenotyp
diabet
nondiabet
may
explain
least
part
insignific
cardioprotect
effect
patient
clinic
studi
investig
factor
may
import
allerg
asthma
diseas
caus
swell
narrow
airway
result
wheez
short
breath
cough
umetsu
mcintir
akbari
macauba
dekruyff
whether
play
role
pathogenesi
asthma
allergiclik
airway
inflamm
still
controversi
determin
biopsi
express
lamina
propria
human
bronchi
firstli
describ
group
van
der
velden
van
der
velden
et
al
differ
asthmat
healthi
control
subsequ
rat
model
asthma
indic
signific
increas
cell
lung
amount
aris
along
sever
airway
inflamm
skripuletz
et
al
recent
nietofontarigo
detect
higher
number
molecul
cell
allerg
nonallerg
asthma
patient
compar
healthi
subject
howev
circul
level
reduc
asthma
patient
may
explain
expans
lymphocyt
popul
peripher
blood
nietofontarigo
et
al
studi
yan
et
al
indic
enhanc
ovalbumininduc
airway
inflamm
mice
increas
cytokin
fig
yan
et
al
contrari
anoth
studi
report
defici
lead
decreas
airway
inflamm
found
significantli
increas
influx
treg
lung
rat
increas
product
drain
lymph
node
cell
schmiedl
et
al
current
populationbas
studi
analysi
cprd
associ
asthma
despit
inconsist
limit
evid
preclin
result
indic
import
role
regul
allerg
immun
respons
thu
rais
safeti
question
clinic
applic
gliptin
highli
suggest
applic
patient
asthma
care
estim
risk
infecti
diseas
induc
wide
investig
metaanalysi
includ
clinic
trial
conclud
could
increas
risk
infect
nasopharyng
risk
ratio
urinari
tract
infect
risk
ratio
upper
respiratori
tract
infect
amori
lau
pitta
use
ukbas
cprd
gambl
also
identifi
initi
associ
increas
risk
respiratori
tract
infect
compar
glucoselow
therapi
gambl
et
al
howev
experiment
studi
investig
molecularimmunerel
mechan
bacteri
infect
newer
antidiabet
agent
sodium
glucos
cotransport
inhibitor
use
due
potenti
benefit
hf
diabet
nephropathi
heerspink
et
al
marx
grant
cosentino
thu
combin
use
wide
patient
report
genit
mycot
infect
one
common
advers
effect
adimadhyam
et
al
note
risk
genit
infect
combin
therapi
dapagliflozin
saxagliptin
lower
observ
dapagliflozin
alon
suggest
protect
effect
saxagliptin
matthaei
et
al
matthaei
et
al
rosenstock
et
al
although
potenti
mechan
unclear
howev
total
differ
conclus
drawn
min
colleagu
analyz
rct
identifi
risk
genit
infect
increas
min
yoon
moon
hahn
cho
specul
differ
combin
togeth
addon
method
simultan
combinationsequenti
combin
may
contribut
inconsist
risk
infect
investig
figur
underli
mechan
signific
middl
east
respiratori
syndrom
coronaviru
merscov
genet
associ
sever
acut
respiratori
syndrom
sar
coronaviru
hilgenfeld
peiri
interestingli
identifi
function
receptor
merscov
interact
spike
protein
raj
et
al
known
level
plasma
vari
depend
pathophysiolog
condit
lambeir
durinx
scharp
de
meester
inn
colleagu
observ
plasma
mer
patient
significantli
lower
normal
volunt
level
immunesuppress
cytokin
protect
growth
factor
epiderm
growth
factor
egf
significantli
neg
posit
correl
plasma
concentr
respect
inn
et
al
thu
assum
exogen
may
therapeut
potenti
mer
patient
applic
gliptin
mer
patient
may
advers
affect
patholog
immun
process
diseas
convers
increas
activ
found
chronic
infect
hepat
c
viru
hcv
hepat
viru
hav
epsteinbarr
viru
andrieu
et
al
pathogenesi
hcv
infect
strongli
influenc
natur
host
antivir
immun
describ
truncat
tabl
riva
et
al
report
subject
develop
chronic
hepat
c
higher
concentr
truncat
activ
wherea
activ
progress
decreas
time
patient
spontan
clear
infect
riva
et
al
followup
studi
conduct
test
effect
inhibit
process
chronic
hcv
patient
particip
treat
daili
mg
sitagliptin
result
signific
decreas
truncat
reciproc
increas
full
length
form
decalf
et
al
data
provid
direct
evid
therapeut
abrog
activ
gliptin
human
preserv
bioactiv
form
suggest
may
novel
strategi
target
viru
host
fig
addit
block
rant
cleavag
therebi
potenti
facilit
human
immunodefici
viru
hiv
entri
lymphocyt
lusso
et
al
inhibit
cleavag
potenti
block
hiv
entri
lymphocyt
bleul
et
al
accordingli
signific
evalu
immun
virolog
safeti
inhibit
hiv
dube
et
al
evalu
inflamm
immun
marker
treatment
sitagliptin
among
virolog
suppress
hiv
patient
without
diabet
found
sitagliptin
effect
level
biomark
monocyt
activ
dube
et
al
addit
differ
immun
marker
except
signific
fall
dube
et
al
similar
investig
perform
goodwin
indic
despit
lower
level
sitagliptin
advers
affect
immun
virolog
statu
increas
immun
activ
nondiabet
hivposit
adult
goodwin
et
al
patient
present
increas
risk
peripher
arteri
diseas
pad
howev
pharmacolog
option
pad
limit
yang
et
al
describ
section
chemokin
attract
epc
promot
angiogenesi
engin
resist
deliv
nanofib
improv
blood
flow
mous
model
pad
seger
et
al
shih
et
al
sitagliptin
huang
et
al
found
increas
number
circul
epc
elev
level
promot
neovasculogenesi
hind
limb
ischemia
mous
model
result
indic
administr
may
therapeut
potenti
induc
vasculogenesi
besid
pad
linagliptin
significantli
improv
outcom
function
stroke
mous
model
transient
middl
cerebr
arteri
occlus
mcao
author
conclud
benefici
effect
linagliptin
may
accomplish
manner
chiazza
et
al
also
regul
hematopoiet
stem
cell
hsc
hematopoiet
progenitor
cell
hpc
truncat
multipl
csf
tabl
report
broxmey
et
al
inhibit
augment
abil
gcsf
gmcsf
induc
myeloid
coloni
format
epo
induc
erythroid
coloni
format
vitro
broxmey
et
al
addit
acceler
hematopoiet
recoveri
myeloabl
chemotherapi
radiotherapi
stem
cell
transplant
observ
mice
lesser
extent
pharmacolog
inhibit
sitagliptin
broxmey
et
al
among
peripher
blood
cell
recoveri
neutrophil
lymphocyt
monocyt
signific
red
blood
cell
rbc
broxmey
et
al
although
potenti
concern
need
address
clinic
trial
treatment
hold
consider
promis
new
strategi
stimul
hematopoiet
recoveri
chemotherapi
stem
cell
transplant
furthermor
due
potenti
influenc
epo
rbc
recoveri
interest
investig
hematopoiesi
effect
gliptin
patient
diabet
nephropathi
anemia
bp
potenti
sever
autoimmun
skin
diseas
typic
clinic
featur
includ
widespread
blister
often
preced
associ
urticari
eczemalik
lesion
tasanen
varpuluoma
nishi
current
bp
attract
increasingli
attent
howbeit
pathogenesi
underli
mechan
remain
unclear
shown
inhibit
rat
induc
infiltr
eosinophil
skin
fig
forssmann
et
al
typic
histopatholog
featur
bp
major
bp
autoantigen
known
transmembran
collagen
xvii
respons
anchor
epidermi
underli
dermi
condit
bp
autoantibodi
could
impair
function
lead
dermalepiderm
separ
algaissi
et
al
note
convert
plasminogen
plasmin
known
cleav
kda
fragment
hofmann
et
al
nishimura
et
al
accordingli
specul
suppress
may
involv
disrupt
immunotoler
subsequ
develop
epitop
bp
autoantibodi
studi
need
elucid
detail
mechan
last
year
case
report
pharmacovigil
analys
suggest
risk
bp
applic
highest
risk
observ
linagliptin
vildagliptin
aouidad
et
al
bene
et
al
studi
european
french
pharmacovigil
databas
first
epidemiolog
investig
identifi
high
bp
incid
gliptin
treat
patient
bene
et
al
garcia
aranburu
palacioszabalza
lertxundi
aguirr
recent
douro
et
al
conduct
cohort
studi
use
uk
cprd
among
patient
take
oad
found
current
use
doubl
risk
bp
albeit
absolut
incid
low
moreov
hazard
risk
gradual
increas
along
extens
use
reach
peak
month
applic
gliptin
douro
et
al
likewis
similar
increas
also
observ
japanes
pharmacovigil
databas
particularli
among
patient
treat
vildagliptin
linagliptin
teneligliptin
arai
shirakawa
konishi
sagawa
terauchi
sever
observ
studi
casecontrol
design
also
conduct
report
significantli
increas
trend
toward
increas
risk
bp
associ
usag
odd
ratio
rang
benzaquen
et
al
kridin
bergman
lee
lee
yoon
kim
plaquev
et
al
varpuluoma
et
al
moreov
benzaquen
et
al
report
applic
increas
risk
bp
almost
increas
associ
vildagliptin
rather
gliptin
benzaquen
et
al
affirm
anoth
similar
nationwid
studi
korea
vildagliptin
display
highest
risk
among
base
find
vildagliptin
appear
strongli
associ
bp
medicin
differ
sinc
rel
lower
select
baetta
corsini
accordingli
specul
offtarget
inhibit
member
dpp
famili
may
caus
pathophysiolog
gliptinrel
bp
howev
patient
treat
linagliptin
high
select
show
equal
risk
bp
well
baetta
corsini
compar
vildagliptin
kridin
bergman
therefor
assum
rather
offtarget
effect
contribut
high
risk
bp
suffer
doubt
whether
alon
drive
bp
factor
concomit
autoimmun
diseas
also
involv
howev
publish
studi
compar
incid
bp
patient
autoimmun
diseas
patient
without
comorbid
addit
unclear
whether
patient
differ
genet
characterist
human
leukocyt
antigen
hla
haplotyp
question
recent
work
studi
conduct
ujii
ujii
et
al
result
suggest
may
strongli
associ
gliptinrel
bp
ujii
et
al
rapid
growth
investig
potenti
associ
gliptin
bp
clinic
immunolog
genet
featur
patient
bp
gradual
unveil
note
although
absolut
incid
low
bp
still
fatal
patient
langan
et
al
henc
physician
awar
risk
review
introduc
function
immun
system
summar
applic
immunomodul
rang
diseas
set
conclus
gliptin
gener
well
toler
without
specif
contraind
howev
regard
recent
find
might
consid
doubleedg
sword
apart
metabol
benefit
associ
immunolog
effect
induc
inhibit
may
bring
benefit
side
effect
differ
condit
tabl
recommend
physician
cautiou
preexist
inflammatori
diseas
patient
initi
controversi
effect
autoimmun
inflammatori
diseas
may
attribut
wide
tissu
distribut
multifunct
tissuespecif
regul
consider
figur
immunomodulatori
effect
addit
effect
observ
anim
model
inconsist
clinic
trial
indic
anim
model
may
complet
appropri
estim
clinic
outcom
research
focu
studi
human
be
detail
subgroup
design
exampl
accord
diseas
durat
metabol
statu
futur
research
would
also
need
determin
effect
nondiabet
popul
nevertheless
gliptin
repres
excit
novel
drug
class
treatment
autoimmun
inflammatori
diseas
note
essenti
defin
optim
molecular
mechan
drug
class
advoc
clinic
use
author
declar
conflict
interest
